|
|
|
|
|
|
|
|
|
|
|
|
|
Public Offering
Price(1)
|
|
|
Underwriting
Discount
|
|
|
Proceeds, Before
Expenses, to
Elevance Health
|
Per 2026 note
|
|
|
99.981%
|
|
|
0.200%
|
|
|
99.781%
|
2026 notes total
|
|
|
$349,933,500
|
|
|
$700,000
|
|
|
$349,233,500
|
Per 2030 note
|
|
|
99.794%
|
|
|
0.350%
|
|
|
99.444%
|
2030 notes total
|
|
|
$748,455,000
|
|
|
$2,625,000
|
|
|
$745,830,000
|
Per 2031 note
|
|
|
99.760%
|
|
|
0.400%
|
|
|
99.360%
|
2031 notes total
|
|
|
$748,200,000
|
|
|
$3,000,000
|
|
|
$745,200,000
|
Per 2035 note
|
|
|
99.646%
|
|
|
0.450%
|
|
|
99.196%
|
2035 notes total
|
|
|
$1,195,752,000
|
|
|
$5,400,000
|
|
|
$1,190,352,000
|
Per 2055 note
|
|
|
99.453%
|
|
|
0.875%
|
|
|
98.578%
|
2055 notes total
|
|
|
$1,342,615,500
|
|
|
$11,812,500
|
|
|
$1,330,803,000
|
Per 2064 note
|
|
|
99.708%
|
|
|
0.875%
|
|
|
98.833%
|
2064 notes total
|
|
|
$797,664,000
|
|
|
$7,000,000
|
|
|
$790,664,000
|
Total
|
|
|
$5,182,620,000
|
|
|
$30,537,500
|
|
|
$5,152,082,500
|
(1)
|
Plus accrued interest, if any, from October 31, 2024, if settlement occurs after that date.
|
|
|||||||||||||||
Joint Book-Running Managers
|
|||||||||||||||
Citigroup
|
|
|
Morgan Stanley
|
|
|
Wells Fargo Securities
|
|||||||||
|
|
|
|
|
|
|
|
||||||||
Barclays
(2035 notes)
|
|
|
Goldman Sachs & Co. LLC
(2030 notes)
|
|
|
J.P. Morgan
(2026 notes and 2055
notes)
|
|||||||||
Mizuho
(2064 notes)
|
|
|
Truist Securities
(2031 notes)
|
|
||||||
Senior Co-Managers
|
||||||
BofA Securities
|
|
|
Deutsche Bank Securities
|
|
|
PNC Capital Markets LLC
|
|
|
|
|
|
|
|
UBS Investment Bank
|
|
|
|
|
|
US Bancorp
|
|
|||
Junior Co-Managers
|
|||
BNY Capital Markets
|
|
|
Huntington Capital Markets
|
|
|
|
|